Episodes (Page 19)
✨
Review of recent biopharmaceutical M&A activity.
Gabrielle Witt
Jessica Bisignano
✨
Stelara biosimilar launches in the US market.
✨
Latest trends in COVID-19 and influenza discussed.
Charlotte Holmes
Natasha Boliter
✨
Maxwellia's journey in consumer healthcare innovation.
Anna Maxwell
✨
Low-cost Wegovy as an option for self-payers.
✨
Impact of Trump tariffs on the pharmaceutical industry.
✨
Introduction to Grove AI and its agentic AI, Grace.
Sohit Gatiganti
Tran Le
✨
Key issues from FDA Commissioner nominee Makary's hearing.
✨
Mixed reactions to Trump's tariff increases.
✨
Companies facing the least impact from exclusivity loss.
✨
Challenges in innovating within the changing OTC industry.
✨
FDA recalls laid-off staff amid government reduction efforts.
✨
Predictions for the biggest drug launches in 2025.
✨
UK law prohibits Rx advertising, yet online pharmacies market them.
✨
US FDA layoffs under Trump administration discussed.
✨
Biopharma industry news roundup for the week of Feb 10.
Drug Fix: RFK’s First Actions, Pitch To Extend Current US FDA User Fee Agreement, More Trump Impacts
✨
HHS Secretary RFK Jr.'s first assignment: chronic disease commission.
Michael McCaughan
✨
Expert panel unpacks deals, trends, and innovations from JPM.
✨
Impact of Trump's re-election and geopolitical instability on biopharma.
✨
Biopharma industry news: Novo's CagriSema, Pfizer's deal activity.